Follow
Richard M Heywood
Richard M Heywood
Leeds Teaching Hospitals NHS Trust, Cambridge Centre for Brain repair
Verified email at nhs.net
Title
Cited by
Cited by
Year
Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit [n] uril
EA Appel, MJ Rowland, XJ Loh, RM Heywood, C Watts, OA Scherman
Chemical communications 48 (79), 9843-9845, 2012
1002012
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone
SGM Piccirillo, I Spiteri, A Sottoriva, A Touloumis, S Ber, SJ Price, ...
Cancer research 75 (1), 194-202, 2015
672015
Characteristics and outcome of patients with DNACPR orders in an acute hospital; an observational study
ZBMC Fritz, RM Heywood, SC Moffat, LE Bradshaw, JP Fuld
Resuscitation 85 (1), 104-108, 2014
362014
The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/HtrA2
F Maus, D Sakry, F Binamé, K Karram, K Rajalingam, C Watts, ...
PLoS One 10 (9), e0137311, 2015
302015
A review of the role of stem cells in the development and treatment of glioma
RM Heywood, HJ Marcus, DJ Ryan, SGM Piccirillo, TMF Al-Mayhani, ...
Acta neurochirurgica 154, 951-969, 2012
242012
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, ...
Journal for immunotherapy of cancer 10 (7), 2022
222022
Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study
A Kawsar, C Edwards, P Patel, RM Heywood, A Gupta, J Mann, ...
British Journal of Dermatology 187 (6), 981-987, 2022
152022
A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR
TF Al-Mayhani, RM Heywood, V Vemireddy, JD Lathia, SGM Piccirillo, ...
Neuro-oncology 21 (6), 719-729, 2019
152019
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities
SH Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, ...
European Journal of Cancer 164, 62-69, 2022
42022
1047P efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
P Bhave, T Ahmed, AN Shoushtari, A Zaremba, JM Versluis, J Mangana, ...
Annals of Oncology 32, S876-S877, 2021
32021
Checkpoint inhibitor associated bullous cutaneous adverse immune-related events: a multicentre observational study
A Kawsar, C Edwards, CA Harwood, R Matin, PC Lorigan, C Harland, ...
2022
73P Characteristics and outcomes of emergency presentations due to immune-mediated toxicities
S Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, T Cooksley, ...
Annals of Oncology 32, S1403-S1404, 2021
2021
P14. 70 BMScope: A systematic mapping review of brain/leptomeningeal metastasis clinical studies from 2010 to 2020
VWT Cheng, R Heywood, R Zakaria, R Burger, A Fitzpatrick, K Zucker, ...
Neuro-Oncology 23 (Supplement_2), ii51-ii51, 2021
2021
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
SHE Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, ...
Journal of Clinical Oncology 39 (15_suppl), 6586-6586, 2021
2021
NG2/CSPG4 promotes proliferation and resistance to therapy in glioblastoma multiforme
RM Heywood, C Watts
Annals of Medicine and Surgery 3 (1), 18, 2014
2014
NG2/CSPG4 promotes progression of glioblastoma multiforme by enhancing proliferation and resistance to therapy
RM Heywood
University of Cambridge, 2014
2014
NG2/CSPG4 promotes resistance to therapy in glioblastoma multiforme
R Heywood, C Watts
EUROPEAN JOURNAL OF CANCER 49, S784-S784, 2013
2013
The human sub-ependymal zone harbors glioblastoma precursors and represents a distinct therapeutic target.
SGM Piccirillo, I Spiteri, A Sottoriva, A Touloumis, S Ber, SJ Price, ...
Cancer Research 73 (8_Supplement), 5016-5016, 2013
2013
The system can't perform the operation now. Try again later.
Articles 1–18